IMPL - Impel NeuroPharma Non-GAAP EPS of -$0.97 beats by $0.06 revenue of $5.01M misses by $0.24M
2023-03-24 08:27:18 ET
- Impel NeuroPharma press release ( NASDAQ: IMPL ): Q4 Non-GAAP EPS of -$0.97 beats by $0.06 .
- Revenue of $5.01M (+735.0% Y/Y) misses by $0.24M .
- As of December 31, 2022, Impel had approximately $60.7 million in cash and cash equivalents. The Company believes, based on its current operating plan, that it has sufficient capital to fund operations into the third quarter of 2023.
- To-date, Trudhesa continues a strong trajectory with more than 58,400 prescriptions generated in 2022. Based on third-party data, it is estimated that at the end of December Trudhesa accounted for 4.3 percent of branded acute migraine prescriptions (nTRx) among prescribers.
- Shares +3.82% PM
- The Company projects Trudhesa will deliver prescriptions within the range of 80,000 – 110,000 TRx for full year 2023.
For further details see:
Impel NeuroPharma Non-GAAP EPS of -$0.97 beats by $0.06, revenue of $5.01M misses by $0.24M